Article

Advancing quality-control for NGS measurement of actionable mutations in circulating tumor DNA

2021-04-06

Abstract excerpt

<h4>SUMMARY</h4> The primary objective of the FDA-led Sequencing and Quality Control Phase 2 (SEQC2) project is to develop standard analysis protocols and quality control metrics for use in DNA testing to enhance scientific research and precision medicine. This study reports a targeted next generation sequencing (NGS) method that enables more accurate detection of actionable mutations in circulating tumor DNA (ct...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 20b9b3ba-5980-5172-a3a4-4b84271d82ca
DOI: 10.1101/2021.04.06.438497

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Advancing quality-control for NGS measurement of actionable mutations in circulating tumor DNADOI 10.1101/2021.04.06.438497Read

Advancing NGS quality control to enable measurement of actionable mutations in circulating tumor DNA.Semantic proximity Read

Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA MeasurementsSemantic proximity Read

Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS liquid biopsy assaySemantic proximity Read

Synthetic Circulating Cell-free DNA as Quality Control Materials for Somatic Mutation Detection in Liquid Biopsy for Cancer.Semantic proximity Read

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA.Semantic proximity Read

Targeted error-suppressed quantification of circulating tumor DNA using semi-degenerate barcoded adapters and biotinylated baitsSemantic proximity Read

Analytical evaluation of circulating tumor DNA sequencing assays.Semantic proximity Read

Direct comparison of circulating tumor DNA sequencing assays with targeted large gene panelsSemantic proximity Read

Analytical Validation of a Pan-Cancer Next-Generation Sequencing Assay for In-House Liquid Biopsy Testing: An International Multicenter Study.Semantic proximity Read

Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNASemantic proximity Read

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNASemantic proximity Read

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNASemantic proximity Read